Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIX Anixa Biosciences	$3.34 -7.2%	$2.75	$2.07 ▼ $4.20	$115.96M	0.34	100,701 shs	168,084 shs
DARE Daré Bioscience	$3.03 -2.9%	$2.96	$2.67 ▼ $5.76	$26.82M	1.2	36,430 shs	6,489 shs
UNCY Unicycive Therapeutics	$0.68 +6.8%	$0.62	$0.20 ▼ $1.10	$82.20M	2.01	1.96 million shs	4.32 million shs
ZNTL Zentalis Pharmaceuticals	$1.34 -8.2%	$1.32	$1.01 ▼ $8.87	$96.42M	1.61	1.57 million shs	1.02 million shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIX Anixa Biosciences	-7.22%	+21.01%	+30.98%	+12.84%	+26.52%
DARE Daré Bioscience	-2.88%	-5.31%	+4.84%	+5.21%	-42.74%
UNCY Unicycive Therapeutics	+6.82%	-9.68%	+22.05%	+16.48%	+3.18%
ZNTL Zentalis Pharmaceuticals	-8.22%	-11.84%	+12.61%	-24.29%	-86.31%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANIX Anixa Biosciences	3.4079 of 5 stars	3.6	5.0	2.5	3.3	0.0
DARE Daré Bioscience	1.6962 of 5 stars	3.3	3.0	2.9	0.0	0.0
UNCY Unicycive Therapeutics	3.5716 of 5 stars	3.8	5.0	3.3	1.7	0.6
ZNTL Zentalis Pharmaceuticals	2.3139 of 5 stars	3.2	2.0	3.2	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIX Anixa Biosciences	3.25	Buy	$9.00	169.46% Upside
DARE Daré Bioscience	2.50	Moderate Buy	$12.00	296.04% Upside
UNCY Unicycive Therapeutics	3.50	Strong Buy	$6.00	780.54% Upside
ZNTL Zentalis Pharmaceuticals	2.44	Hold	$8.24	515.26% Upside

Current Analyst Ratings Breakdown

Latest DARE, ANIX, UNCY, and ZNTL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/10/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/29/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/27/2025	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$9.00
5/15/2025	ZNTL Zentalis Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$4.00 ➝ $4.00
5/15/2025	ZNTL Zentalis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/21/2025	UNCY Unicycive Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00
4/11/2025	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.50 ➝ $7.50
4/10/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/1/2025	DARE Daré Bioscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
4/1/2025	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $7.50
3/28/2025	ZNTL Zentalis Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$4.00 ➝ $4.00

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIX Anixa Biosciences	$210K	512.31	N/A	N/A	$0.59 per share	5.66
DARE Daré Bioscience	$25.91K	1,034.99	N/A	N/A	($0.61) per share	-4.97
UNCY Unicycive Therapeutics	$680K	120.88	N/A	N/A	($0.11) per share	-6.19
ZNTL Zentalis Pharmaceuticals	$26.87M	3.59	N/A	N/A	$6.18 per share	0.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIX Anixa Biosciences	-$12.55M	-$0.38	N/A	∞	N/A	N/A	-58.55%	-53.29%	N/A
DARE Daré Bioscience	-$30.16M	-$0.17	N/A	N/A	N/A	-191.65%	N/A	-18.98%	8/11/2025 (Estimated)
UNCY Unicycive Therapeutics	-$30.54M	-$0.51	N/A	N/A	N/A	N/A	N/A	-29.88%	N/A
ZNTL Zentalis Pharmaceuticals	-$292.19M	-$3.13	N/A	N/A	N/A	N/A	-43.91%	-34.96%	8/8/2025 (Estimated)

Latest DARE, ANIX, UNCY, and ZNTL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/3/2025	Q2 2025	ANIX Anixa Biosciences	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A
5/14/2025	Q1 2025	UNCY Unicycive Therapeutics	-$0.14	-$0.05	+$0.09	-$0.05	N/A	N/A
5/14/2025	Q1 2025	ZNTL Zentalis Pharmaceuticals	-$0.67	-$0.67	N/A	-$0.67	N/A	N/A
5/13/2025	Q1 2025	DARE Daré Bioscience	-$0.63	-$0.50	+$0.13	-$0.50	$0.60 million	$0.03 million
3/31/2025	Q4 2024	DARE Daré Bioscience	-$0.66	-$0.64	+$0.02	-$0.64	$1.00 million	($0.06) million
3/27/2025	Q4 2024	UNCY Unicycive Therapeutics	-$0.13	-$0.26	-$0.13	-$0.26	N/A	N/A
3/26/2025	Q4 2024	ZNTL Zentalis Pharmaceuticals	-$0.75	-$0.66	+$0.09	-$0.66	N/A	$26.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIX Anixa Biosciences	N/A	N/A	N/A	N/A	N/A
DARE Daré Bioscience	N/A	N/A	N/A	N/A	N/A
UNCY Unicycive Therapeutics	N/A	N/A	N/A	N/A	N/A
ZNTL Zentalis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIX Anixa Biosciences	N/A	8.54	8.54
DARE Daré Bioscience	N/A	1.14	1.14
UNCY Unicycive Therapeutics	N/A	3.61	3.61
ZNTL Zentalis Pharmaceuticals	N/A	7.29	7.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIX Anixa Biosciences	29.13%
DARE Daré Bioscience	6.70%
UNCY Unicycive Therapeutics	40.42%
ZNTL Zentalis Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ANIX Anixa Biosciences	25.30%
DARE Daré Bioscience	4.00%
UNCY Unicycive Therapeutics	10.71%
ZNTL Zentalis Pharmaceuticals	1.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIX Anixa Biosciences	5	32.21 million	24.05 million	Optionable
DARE Daré Bioscience	30	8.85 million	8.35 million	Not Optionable
UNCY Unicycive Therapeutics	9	120.63 million	78.78 million	Not Optionable
ZNTL Zentalis Pharmaceuticals	160	71.95 million	68.70 million	Optionable

DARE, ANIX, UNCY, and ZNTL Headlines

Recent News About These Companies

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by Bank of America Corp DE

June 10, 2025 | marketbeat.com

Two Sigma Investments LP Sells 291,801 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

June 3, 2025 | marketbeat.com

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 2, 2025 | globenewswire.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by Two Sigma Advisers LP

May 29, 2025 | marketbeat.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Stock Holdings Lessened by Woodline Partners LP

May 27, 2025 | marketbeat.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of "Hold" by Analysts

May 25, 2025 | marketbeat.com

Jacobs Levy Equity Management Inc. Takes $703,000 Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

May 20, 2025 | marketbeat.com

HC Wainwright Brokers Raise Earnings Estimates for ZNTL

May 20, 2025 | marketbeat.com

Wedbush Issues Optimistic Outlook for ZNTL Earnings

May 20, 2025 | marketbeat.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by MPM Bioimpact LLC

May 16, 2025 | marketbeat.com

Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress

May 14, 2025 | globenewswire.com

Integral Health Asset Management LLC Makes New Investment in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

May 14, 2025 | marketbeat.com

First Patient Dosed With Azenosertib in Cyclin E1+ Ovarian Cancer

May 3, 2025 | curetoday.com

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 1, 2025 | globenewswire.com

Scott Dunseth Myers Purchases 21,000 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Stock

May 1, 2025 | insidertrades.com

Zentalis shares insights on cancer research at AACR

April 29, 2025 | investing.com

Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC

April 28, 2025 | globenewswire.com

Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting

April 23, 2025 | globenewswire.com

Why Zentalis Pharmaceuticals, Inc.’s (ZNTL) Stock Is Down 8.97%

April 10, 2025 | aaii.com

Why Zentalis Pharmaceuticals, Inc.’s (ZNTL) Stock Is Down 12.58%

April 2, 2025 | aaii.com

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 1, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DARE, ANIX, UNCY, and ZNTL Company Descriptions

Anixa Biosciences NASDAQ:ANIX

$3.34 -0.26 (-7.22%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$3.48 +0.15 (+4.34%)

As of 06/13/2025 07:58 PM Eastern

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Daré Bioscience NASDAQ:DARE

$3.03 -0.09 (-2.88%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$3.06 +0.04 (+1.16%)

As of 06/13/2025 04:04 PM Eastern

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

Unicycive Therapeutics NASDAQ:UNCY

$0.68 +0.04 (+6.82%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$0.68 +0.00 (+0.23%)

As of 06/13/2025 07:59 PM Eastern

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Zentalis Pharmaceuticals NASDAQ:ZNTL

$1.34 -0.12 (-8.22%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.38 +0.03 (+2.61%)

As of 06/13/2025 07:50 PM Eastern

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time